Similar to apoA-I and apoA-I mimetic peptides, intraperitoneal application of human apoA-IV ameliorated eosinophilic airway inflammation as observed by reduced eosinophil counts in the BAL fluid in house dust mite-challenged mice and prevented airway hyperreactivity as assessed by reduced airway resistance and improved airway compliance [29]. This evidence concerns the gene APOA1 and inflammation.